Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA Gene Overexpression

CAMBRIDGE, Mass.--(BUSINESS WIRE) April 09, 2024 -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials